Biospecimen Core
- Institution
- SLOAN-KETTERING INST CAN RESEARCH, NY
- Principal investigator
- Olca Basturk
- Funding
- $127K
- Duration
- 2022–2027
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY – BIOSPECIMEN CORE The Biospecimen Core is designed to provide expert support to the translational research efforts of the Memorial Sloan Kettering Cancer Center (MSK) Pancreas SPORE. The Core will leverage and extend the very active tissue banking program and molecular diagnostics capabilities of the MSK Precision Pathology Biobanking Core (PPBC), which anchors 4 other MSK SPOREs and the MSK Center for Pancreatic Cancer Research. The SPORE Biospecimen Core will play an essential role in collection, annotation, storage, distribution, and tracking of pancreatic cancer biospecimens (tissue and blood) from patients enrolled in institutional biospecimen banking protocols and therapeutic research protocols. Detailed biospecimen annotation, including documentation of preanalytic processing variables, pathology findings, and patient clinical history information will be recorded in robust relational databases. We will conduct rigorous data quality assurance and quality control measures, and standardized longitudinal follow-up of all consented patients with materials in the pancreatic cancer biospecimen repository. The Core will also provide SPORE investigators with expert histopathological evaluation of tumor samples, as well as assistance in performing and interpreting immunohistochemical assays, selecting tissue for microdissection for downstream analysis, constructing tissue microarrays, and facilitating patient-derived organoid creation. The specific aims of the core are to (1) maintain and expand the collection, annotation, and storage of biospecimens for pancreatic cancer research, (2) perform systematic pathologic evaluation of all relevant ductal pancreatic adenocarcinoma samples and to prepare appropriate biospecimens for use by SPORE investigators, and (3) provide systematic microscopic assessment of response to therapy. Given the significant heterogeneity of pancreatic cancers, each of these aims requires expertise beyond what existing resources can provide, underscoring the need for this Core. All of the research projects will rely extensively on the Biospecimen Core to achieve their translational research objectives.
LOADING MOONBASE SCORE
Questions for SLOAN-KETTERING INST CAN RESEARCH
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · Sloan-Kettering Inst Can Research60
Expansion of Tumoroid Models for Precise Treatment of the Rectal Cancer Patient
Jesse Joshua Smith · $80K · 2025
- NIH · Sloan-Kettering Inst Can Research51
Phase II Study of ASTX727 in Patients with PRC2 loss Malignant Peripheral Nerve Sheath Tumor (MPNST)
Ping Chi · $576K · 2022–2026
- NIH · Sloan-Kettering Inst Can Research49
Targeting stem-like cells and their niche in pancreatic cancer
Tuomas Tammela · $491K · 2025–2026